Unrecognized Risk: How Hereditary Cancer Genetic Testing Can Transform Surgical Planning and Long-Term Management
ASCRS 2026 ANNUAL MEETING
MONDAY LUNCH SYMPOSIUM
This dynamic lunch symposium spotlights how routine pre‑operative hereditary cancer genetic testing with the MyRisk® Hereditary Cancer Test can sharpen surgical planning and elevate long‑term patient management. Through concise, evidence‑based insights from leading CRC experts, attendees will see how early genetic risk identification can inform operative decisions, streamline multidisciplinary coordination, and support more precise colorectal cancer care. This session will also explore practical workflows utilizing Myriad’s suite of services and showcase how a leading cancer center has implemented them in real-world practice.
Lunch and beverages will be provided. This symposium is exclusively for registered ASCRS 2026 attendees.
Seats are limited. RSVP now.
Speakers
Paul Johnson, MD, M.M.Sc, FACS, FASCRS
Methodist Cancer Institute
Dr. Paul Johnson, MD, FACS is a double board-certified colon and rectal surgeon with the Methodist Cancer Institute in Memphis, where he provides evidence based, patient centered surgical care. He serves as an adjunct assistant professor of surgery and is a Fellow of both the American College of Surgeons and the American Society of Colon and Rectal Surgeons, including service as one of four ASCRS delegates to the House of Delegates. An award-winning educator and published scholar, Dr. Johnson has authored multiple peer-reviewed publications and serves as a frequent reviewer for the Diseases of the Colon and Rectum journal.
Vitaliy Y. Poylin, MD
Northwestern Medicine Digestive Health Center
Dr. Vitaliy Poylin is Director of the Section of Colon and Rectal Surgery at Northwestern Medicine and an Associate Professor of Surgery at Northwestern University Feinberg School of Medicine. He currently serves as Chair of the American Society of Colon and Rectal Surgeons Inflammatory Bowel Disease Committee. Dr. Poylin’s clinical and research focus includes inflammatory bowel disease and colorectal cancer, with an emphasis on minimally invasive surgery, quality improvement, and national clinical research initiatives.
About Myriad Oncology™
Myriad Oncology, a business unit of genetic testing and precision medicine leader Myriad Genetics, provides an expanding portfolio of advanced genetic and tumor genomic testing solutions, meeting the specific needs of clinicians and their oncology patients. Myriad Oncology products support each step in the cancer care continuum, empowering clinicians and their patients with confidence and clarity to navigate the unique challenges of each cancer journey. For more information, visit https://myriad.com/oncology/.
We Are Live In
Location
Myriad Genetics, Inc. / 322 North 2200 West, Salt Lake City, UT 84116 ©2026 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, MyRisk, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.